CANINE COMPARATIVE ONCOLOGY & GENOMICS CONSORTIUM

CCOGC Background

In June of 2004, an informal collaboration of veterinary and medical oncologists, pathologists, surgeons, geneticists, and molecular and cellular biologists emerged at a meeting hosted by the Broad Institute, in Boston, MA. These investigators shared a common interest, the comparative study of canine and human genomics and cancer. With the imminent availability of a high quality canine genome assembly, they sought to leverage opportunities that would result from a better defined understanding of the genetics and biology of cancers in companion animals, to provide a forum for discussion and sharing of resources and reagents, and to guide the development of novel technologies that would allow the study and use of appropriate canine cancers in the global study of cancer biology and therapy. Over the ensuing months this collaboration named itself the Canine Comparative Oncology and Genomics Consortium (CCOGC) and began drafting an agenda and list of priorities. In 2007 the CCOGC incorporated as a Not-For-Profit and obtained 501(c)3 status. The goals of the CCOGC are to facilitate strategic partnerships and collaborations across a diversity of disciplines, focused on the problem of cancer in dogs. Early priorities of the CCOGC include advocacy for the field of Comparative Oncology and the development of a biospecimen repository.

 

Pfizer CCOGC Biospecimen Repository Tissue Selection

It was decided that the specific cancers to be selected should represent those that were not only major problems in the dog population, but which also have significant comparative value in human cancer investigation. Accordingly cancer specific goals included the collection of samples from dogs with lymphoma, osteosarcoma and melanoma. Samples collected from each patient should include tumor, normal tissue, blood, and urine. An additional four histologies (hemangiosarcoma, pulmonary tumors, soft tissue sarcoma and mast cell tumors) selected in consultation with the broader community and sponsoring agencies were added to the collections in 2007.

 

Collection Site Selection

Since 2007, the Pfizer CCOGC Biospecimen Repository has issued two RFPs for collection sites. Sites were selected based on caseload, experience with sample collection, personnel and physical infrastructure, and institutional commitment to the banking effort. The Pfizer CCOGC Biospecimen Repository currently has 6 collection sites.